open access
Effectiveness of EFFACLAR H ISO-BIOME preparations as an adjunct to conventional treatment of acne vulgaris — results of an observational study
, 2, 3, 4, 5, 1
Affiliations- Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland
- L’Oréal Dermatological Beauty, L’Oréal Poland
- Department and Clinic of Dermatology, Medical University of Silesia, Katowice, Poland
- Department and Institute of Cosmetology, Collegium Medicum in Bydgoszcz, Poland
- Department and Clinic of Dermatology, Medical University of Silesia, Katowice, Poland
open access
Abstract
Background: Although topical dermocosmetics are widely used care products, only a few studies investigated their effectiveness in enhancing the tolerance and efficacy of medical anti-acne therapies. The primary objective of this study was to assess the safety and efficacy of EFFACLAR H ISO-BIOME cream and washing cream as an adjunct to pharmacological treatment (local and/or systemic) administered for at least 12 weeks in patients with mild to very severe acne vulgaris.
Material and methods: This observational study was conducted in patients (n = 306) aged 14 years and over with mild to very severe [Global Acne Severity Scale (GEA) 1–5] acne vulgaris. Participants were instructed to apply the EFFACLAR H ISO-BIOME cream and washing cream twice daily for at least 12 weeks along with prescribed anti-acne therapy (topical agents, oral isotretinoin, or systemic antibiotics/ /spironolactone combined with topical agents).
Results: The treatment regimen led to an improvement in GEA scores in 88.9% of all patients (p < 0.05). Statistically significant changes were observed in the reduction of sebum secretion, number of papules and pustules, postinflammatory hyperpigmentation, and erythema (p < 0.05). The vast majority of dermatologists and patients rated the tolerance of the products as very good (97% and 94%, respectively). The quality of life of most patients improved by the end of the study.
Conclusions: EFFACLAR H ISO-BIOME cream and washing cream are safe and effective products used as adjunctive treatment to topical or systemic therapy of mild to very severe acne vulgaris.
Abstract
Background: Although topical dermocosmetics are widely used care products, only a few studies investigated their effectiveness in enhancing the tolerance and efficacy of medical anti-acne therapies. The primary objective of this study was to assess the safety and efficacy of EFFACLAR H ISO-BIOME cream and washing cream as an adjunct to pharmacological treatment (local and/or systemic) administered for at least 12 weeks in patients with mild to very severe acne vulgaris.
Material and methods: This observational study was conducted in patients (n = 306) aged 14 years and over with mild to very severe [Global Acne Severity Scale (GEA) 1–5] acne vulgaris. Participants were instructed to apply the EFFACLAR H ISO-BIOME cream and washing cream twice daily for at least 12 weeks along with prescribed anti-acne therapy (topical agents, oral isotretinoin, or systemic antibiotics/ /spironolactone combined with topical agents).
Results: The treatment regimen led to an improvement in GEA scores in 88.9% of all patients (p < 0.05). Statistically significant changes were observed in the reduction of sebum secretion, number of papules and pustules, postinflammatory hyperpigmentation, and erythema (p < 0.05). The vast majority of dermatologists and patients rated the tolerance of the products as very good (97% and 94%, respectively). The quality of life of most patients improved by the end of the study.
Conclusions: EFFACLAR H ISO-BIOME cream and washing cream are safe and effective products used as adjunctive treatment to topical or systemic therapy of mild to very severe acne vulgaris.
Keywords
dermocosmetics, EFFACLAR H ISO-BIOME, acne
About this articleTitle
Effectiveness of EFFACLAR H ISO-BIOME preparations as an adjunct to conventional treatment of acne vulgaris — results of an observational study
Journal
Issue
Article type
Other materials agreed with the Editors
Pages
83-89
Published online
2023-09-29
Page views
250
Article views/downloads
302
DOI
Bibliographic record
Forum Dermatologicum 2023;9(3):83-89.
Keywords
dermocosmetics
EFFACLAR H ISO-BIOME
acne
Authors
Dominika Kwiatkowska
Diana Wolańska-Buzalska
Mikołaj Łanocha
Barbara Zegarska
Beata Bergler-Czop
Adam Reich
References (17)- Nast A, Dréno B, Bettoli V, et al. European Dermatology Forum. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012; 26 Suppl 1(8): 1–29.
- Heng AH, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020; 10(1): 5754.
- Dréno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017; 31 Suppl 5: 8–12.
- Cordain L, Lindeberg S, Hurtado M, et al. Acne vulgaris: a disease of Western civilization. Arch Dermatol. 2002; 138(12): 1584–1590.
- Dréno B, Poli F, Pawin H, et al. Development and evaluation of a Global Acne Severity Scale (GEA Scale) suitable for France and Europe. J Eur Acad Dermatol Venereol. 2011; 25(1): 43–48.
- Chen H, Zhang TC, Yin XL, et al. Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019. Br J Dermatol. 2022; 186(4): 673–683.
- Moradi Tuchayi S, Alexander TM, Nadkarni A, et al. Interventions to increase adherence to acne treatment. Patient Prefer Adherence. 2016; 10: 2091–2096.
- Dréno B, Thiboutot D, Gollnick H, et al. Global Alliance to Improve Outcomes in Acne. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010; 49(4): 448–456.
- Chernyshov PV, Zouboulis CC, Tomas-Aragones L, et al. Quality of life measurement in acne. Position paper of the European Academy of Dermatology and venereology task forces on quality of life and patient oriented outcomes and acne, rosacea and hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2018; 32(2): 194–208.
- Gieler U, Gieler T, Kupfer JP. Acne and quality of life — impact and management. J Eur Acad Dermatol Venereol. 2015; 29 Suppl 4: 12–14.
- Huang C, Zhuo F, Han B, et al. The updates and implications of cutaneous microbiota in acne. Cell Biosci. 2023; 13(1): 113.
- Lam M, Hu A, Fleming P, et al. The impact of acne treatment on skin bacterial microbiota: a systematic review. J Cutan Med Surg. 2022; 26(1): 93–97.
- Moloney J. The skin microbiome in patients with acne vulgaris. EMJ Dermatology. 2015: 45–50.
- Conforti C, Giuffrida R, Fadda S, et al. Topical dermocosmetics and acne vulgaris. Dermatol Ther. 2021; 34(1): e14436.
- Kurokawa I, Kobayashi M, Nomura Y, et al. The role and benefits of dermocosmetics in acne management in japan. Dermatol Ther (Heidelb). 2023; 13(7): 1423–1433.
- Araviiskaia E, Dréno B. The role of topical dermocosmetics in acne vulgaris. J Eur Acad Dermatol Venereol. 2016; 30(6): 926–935.
- Zegarska B, Rudnicka L, Narbutt J, et al. Dermocosmetics in dermatological practice. Recommendations of the Polish Dermatological Society. Part I. Dermatology Review. 2023; 110(2): 121–132.
